GleamWall
中文EN

VIR Vir Biotechnology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1706431 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,696.0%
TTM net income YoY63.0%
TTM EPS YoY67.4%
Revenue 3-yr CAGR36.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-69.8%
Net margin-61.0%
FCF margin-46.8%
EBITDA margin-66.1%

Returns

ROE-21.8%
ROA-17.3%
ROIC (approx.)-25.6%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue-$188,000$238.95M-$29,000$64.07M$240,000$1.21M$3.03M$12.37M
Cost of revenue—$0———$11,000$0$684,000
Gross profit—$238.95M———$1.20M$3.03M$11.69M
R&D expense$80.04M$135.28M$108.92M$88.35M$151.46M$97.51M$118.64M$106.08M
SG&A expense$24.43M$30.20M$23.34M$23.62M$22.23M$22.28M$23.94M$26.70M
Operating income-$104.66M$73.47M-$132.29M-$47.92M-$173.44M-$118.42M-$139.55M-$117.15M
Pretax income-$96.39M$80.26M-$125.53M-$43.06M-$162.97M-$110.79M-$120.95M-$104.67M
Income tax-$143,000$179,000$170,000-$137,000$168,000$170,000$16,000-$86,000
Net income-$96.25M$80.08M-$125.69M-$42.92M-$163.14M-$110.96M-$120.97M-$104.59M
EBITDA-$101.96M$76.17M-$129.48M-$45.02M-$170.54M-$115.52M-$136.68M-$114.26M
EPS (basic)-0.570.48-0.85—-1.17-0.80-0.88—
EPS (diluted)-0.570.47-0.85—-1.17-0.80-0.88—
Weighted avg. shares (diluted)169.28M168.88M147.36M—138.93M138.45M137.47M—
Balance sheet
Cash & equivalents$218.87M$278.73M$274.16M$232.19M$170.08M$211.10M$273.57M$318.69M
Short-term investments$235.77M$249.86M$196.28M$228.75M$327.75M$387.64M$517.37M$678.05M
Current assets$508.27M$573.74M$522.99M$514.08M$545.68M$735.71M$932.21M$1.04B
PP&E, net$47.77M$50.43M$53.16M$55.62M$58.20M$60.80M$61.68M$63.18M
Goodwill$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M$16.94M
Intangibles$7.63M$7.70M$7.78M$7.85M$7.92M$8.00M$8.07M$8.12M
Total assets$1.11B$1.21B$1.03B$1.00B$1.02B$1.19B$1.31B$1.40B
Current liabilities$80.66M$94.96M$73.56M$92.81M$75.22M$105.00M$137.29M$119.66M
Total liabilities$215.82M$232.31M$212.82M$237.55M$223.35M$245.06M$263.91M$248.43M
Shareholders' equity$896.04M$982.49M$812.76M$765.28M$796.10M$947.47M$1.04B$1.15B
Shares outstanding169.41M169.19M161.23M139.47M139.02M138.89M138.06M136.96M
Cash flow statement
Operating cash flow-$106.08M$123.33M-$132.39M-$25.88M-$167.57M-$120.22M-$78.12M-$87.64M
Capital expenditure$34,000$32,000$390,000$348,000$317,000$2.54M$1.63M$2.41M
Free cash flow-$106.11M$123.29M-$132.78M-$26.22M-$167.89M-$122.76M-$79.75M-$90.04M
Investing cash flow$44.56M-$197.14M$11.84M$86.65M$40.45M$56.46M$126.82M$140.74M
Financing cash flow$1.63M$78.38M$162.52M$1.04M$102,000$2.05M$598,000$1.26M
Depreciation & amortization$2.70M$2.70M$2.81M$2.90M$2.90M$2.90M$2.87M$2.89M
Stock-based compensation$10.46M$12.39M$12.09M$11.21M$11.36M$12.45M$14.06M$15.84M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.